Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University, Wexner Medical Center, Columbus, OH.
Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH.
Hepatology. 2019 Aug;70(2):630-639. doi: 10.1002/hep.30274. Epub 2019 Feb 19.
Early readmission in patients with decompensated liver cirrhosis leads to an enormous burden on health care use. A retrospective cohort study using the 2013 and 2014 Nationwide Readmission Database (NRD) was conducted. Patients with a diagnoses of cirrhosis and at least one feature of decompensation were included. The primary outcome was to develop a validated risk model for early readmission. Secondary outcomes were to study the 30-day all-cause readmission rate and the most common reasons for readmission. A multivariable logistic regression model was fit to identify predictors of readmissions. Finally, a risk model, the Mumtaz readmission risk score, was developed for prediction of 30-day readmission based on the 2013 NRD and validated on the 2014 NRD. A total of 123,011 patients were included. The 30-day readmission rate was 27%, with 79.6% of patients readmitted with liver-related diagnoses. Age <65 years; Medicare or Medicaid insurance; nonalcoholic etiology of cirrhosis; ≥3 Elixhauser score; presence of hepatic encephalopathy, ascites, variceal bleeding, hepatocellular carcinoma, paracentesis, or hemodialysis; and discharge against medical advice were independent predictors of 30-day readmission. This validated model enabled patients with decompensated cirrhosis to be stratified into groups with low (<20%), medium, (20%-30%), and high (>30%) risk of 30-day readmissions. Conclusion: One third of patients with decompensated cirrhosis are readmitted within 30 days of discharge. The use of a simple risk scoring model with high generalizability, based on demographics, clinical features, and interventions, can bring refinement to the prediction of 30-day readmission in high-risk patients; the Mumtaz readmission risk score highlights the need for targeted interventions in order to decrease rates of readmission within this population.
失代偿期肝硬化患者的早期再入院给医疗保健带来了巨大负担。本研究采用 2013 年和 2014 年全国再入院数据库(NRD)进行回顾性队列研究。纳入诊断为肝硬化且至少有一项失代偿特征的患者。主要结局是开发一个验证的早期再入院风险模型。次要结局是研究 30 天全因再入院率和再入院的最常见原因。使用多变量逻辑回归模型来确定再入院的预测因素。最后,根据 2013 年 NRD 开发了一个风险模型,即 Mumtaz 再入院风险评分,用于预测基于 2013 年 NRD 验证的 2014 年 NRD 的 30 天再入院。共纳入 123011 例患者。30 天再入院率为 27%,79.6%的患者因与肝脏相关的诊断再入院。年龄<65 岁;医疗保险或医疗补助保险;非酒精性肝硬化病因;Elixhauser 评分≥3 分;肝性脑病、腹水、静脉曲张出血、肝细胞癌、腹腔穿刺术或血液透析存在;以及出院时违背医嘱是 30 天再入院的独立预测因素。该验证模型使失代偿性肝硬化患者能够分为低(<20%)、中(20%-30%)和高(>30%)30 天再入院风险组。结论:三分之一的失代偿期肝硬化患者在出院后 30 天内再次入院。使用基于人口统计学、临床特征和干预措施的简单风险评分模型,具有高度的普遍性,可以提高高危患者 30 天再入院预测的准确性;Mumtaz 再入院风险评分突出了需要针对这一人群进行有针对性的干预,以降低再入院率。